Skip to Main Content

Author Details

Bj??rn Scheffler
German Cancer Research Center (DKFZ)
1992
84
31
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36054558A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression.Int J Cancer2023
37627083Telemedicine in Neuro-Oncology-An Evaluation of Remote Consultations during the COVID-19 Pandemic.Cancers (Basel)2023
37547266Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.Neurooncol Adv2023
37418389TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.PLoS One2023
37335907Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression.Neuro Oncol2023
37334753Surface Chemistry and Specific Surface Area Rule the Efficiency of Gold Nanoparticle Sensitizers in Proton Therapy.Chemistry2023
37296942Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis.Cancers (Basel)2023
36239995A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.Clin Cancer Res2023
35953681Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.J Cancer Res Clin Oncol2023
35326526Machine Learning Applications for Differentiation of Glioma from Brain Metastasis-A Systematic Review.Cancers (Basel)2022
35831316The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors.Nat Commun2022
36284931First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT</i> promoter methylated <i>IDH</i> wildtype glioblastoma.Neurooncol Adv2022
35013174Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.Nat Commun2022
33389825Dosimetric impact of the positioning variation of tumor treating field electrodes in the PriCoTTF-phase I/II trial.J Appl Clin Med Phys2021
33789203Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.Eur J Cancer2021
33502678Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography.J Neurooncol2021
33937037Case Report: Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant Melanoma.Front Oncol2021
34359673How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis.Cancers (Basel)2021
34162860Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression.Nat Commun2021
32307022Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.Radiat Oncol2020
33506201Preoperative and early postoperative seizures in patients with glioblastoma-two sides of the same coin?Neurooncol Adv2020
32033141Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer.Cancers (Basel)2020
31831598Olfactory function as an independent prognostic factor in glioblastoma.Neurology2020
31828428Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.J Cancer Res Clin Oncol2020
31743443Exosome/microvesicle content is altered in leucine-rich repeat kinase 2 mutant induced pluripotent stem cell-derived neural cells.J Comp Neurol2020
33091717Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.Eur J Cancer2020
33003586Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature.Int J Mol Sci2020
32711135Challenging Implications of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids Syndrome with an Atypical Presentation: Report of Two Cases.World Neurosurg2020
32599645Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.Int J Cancer2020
30516675Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.Clin Nucl Med2019
31646997Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.BMC Cancer2019
315861013D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors.Nat Commun2019
30985412Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.Clin Nucl Med2019
30894200Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.J Transl Med2019
30820715Regorafenib in patients with recurrent high-grade astrocytoma.J Cancer Res Clin Oncol2019
30721788Sequence-dependent cross-resistance of combined radiotherapy plus BRAF<sup>V600E</sup> inhibition in melanoma.Eur J Cancer2019
29754968Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.J Clin Neurosci2018
27521447Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.Clin Cancer Res2017
28030820Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.Oncotarget2017
27100354Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.J Cancer Res Clin Oncol2016
26673798Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.Clin Cancer Res2016
27591333Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.Neuro Oncol2016
26827696Therapy of leptomeningeal metastasis in solid tumors.Cancer Treat Rev2016
25328136DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2.Oncogene2015
26103419Evolutionary trends and functional anatomy of the human expanded autophagy network.Autophagy2015
24942787Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.Oncology2014
23460716Vemurafenib for leptomeningeal melanomatosis.J Clin Oncol2013
24068827Chondroitin sulfate proteoglycans potently inhibit invasion and serve as a central organizer of the brain tumor microenvironment.J Neurosci2013
23908450Anticancer effects of niclosamide in human glioblastoma.Clin Cancer Res2013
23963648Tenascin-C is expressed by human glioma in vivo and shows a strong association with tumor blood vessels.Cell Tissue Res2013
  • 1 - 50 of 84

Recommended Authors

Massachusetts General Hospital
Career Start Year 2015
Number of shared co-authors 7
University of California san francisco
Career Start Year 2012
Number of shared co-authors 0
Barrow Neurological Institute
Career Start Year 2008
Number of shared co-authors 0
University of California san francisco
Career Start Year 2006
Number of shared co-authors 13
McMaster Stem Cell and Cancer Research Institute
Career Start Year 2006
Number of shared co-authors 7
University of California san francisco
Career Start Year 2005
Number of shared co-authors 3
Northwestern University
Career Start Year 2005
Number of shared co-authors 0
Cancer Stem Cell Research Center, Samsung Biomedical Research Institute
Career Start Year 2002
Number of shared co-authors 0
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 2002
Number of shared co-authors 0
Perelman School of Medicine at the University of Pennsylvania
Career Start Year 2002
Number of shared co-authors 4
McMaster University
Career Start Year 2001
Number of shared co-authors 10
Clinical Sciences Building, The University of Melbourne, The Royal Melbourne Hospital
Career Start Year 2001
Number of shared co-authors 0
Lerner Research Institute, Cleveland Clinic
Career Start Year 2001
Number of shared co-authors 1
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 1998
Number of shared co-authors 6
University of California san francisco
Career Start Year 1998
Number of shared co-authors 3
Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children
Career Start Year 1997
Number of shared co-authors 9
Lenox Hill Hospital
Career Start Year 1997
Number of shared co-authors 0
University of Illinois at Urbana-Champaign
Career Start Year 1996
Number of shared co-authors 5
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 2
Samsung Medical Center, Sungkyunkwan University School
Career Start Year 1996
Number of shared co-authors 10
University of California san francisco
Career Start Year 1993
Number of shared co-authors 0
UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Career Start Year 1992
Number of shared co-authors 11
Meyer Cancer Center
Career Start Year 1990
Number of shared co-authors 2
American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University
Career Start Year 1990
Number of shared co-authors 1
Huntsman Cancer Institute, University of Utah
Career Start Year 1990
Number of shared co-authors 8
IRCCS Casa Sollievo della Sofferenza, University of Milano-Bicocca
Career Start Year 1986
Number of shared co-authors 2
The Hospital for Sick Children, University of Toronto
Career Start Year 1986
Number of shared co-authors 11
The University of Texas M.D. Anderson Cancer Center
Career Start Year 1984
Number of shared co-authors 2
IRCCS San Raffaele Scientific Institute
Career Start Year 1983
Number of shared co-authors 10
Center for Translational Neuromedicine, University of Rochester Medical Center
Career Start Year 1982
Number of shared co-authors 0

Collaborators

University Hospital Essen
Co-authored papers 46
Co-authored papers 6
Co-authored papers 6
University Hospital Bonn
Co-authored papers 6
Co-authored papers 3
Heinrich Heine University
Co-authored papers 3
and Clinical Immunology, Heinrich Heine University, University Hospital Dusseldorf
Co-authored papers 2
Bonn-Aachen International Center for IT (B-IT), University of Bonn
Co-authored papers 2
Wilmer Eye Institute, Johns Hopkins Medical Institutions
Co-authored papers 2
Miltenyi Biotec Inc.
Co-authored papers 1
Institut Curie, Inserm, CNRS, Universite Paris-Saclay
Co-authored papers 1
and Clinical Immunology, Heinrich Heine University
Co-authored papers 1
Co-authored papers 1
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 1
Institut Curie, PSL Research University, CNRS UMR, INSERM
Co-authored papers 1
and Clinical Immunology, Heinrich Heine University, University Hospital Dusseldorf
Co-authored papers 1
Institut fur Pysikalische Biologie, Heinrich Heine University Dusseldorf
Co-authored papers 1
Universitatsklinikum
Co-authored papers 1
College of Tropical Crops, Hainan University
Co-authored papers 1
Co-authored papers 1
German Cancer Research Center (DKFZ)
Co-authored papers 1
Stanford University
Co-authored papers 1
Massachusetts General Hospital
Co-authored papers 1
Sanford Burnham Prebys Medical Discovery Institute
Co-authored papers 1
Institut fur Physikalische Biologie, Heinrich-Heine-Universitat Dusseldorf
Co-authored papers 1
National Institute on Aging, National Institutes of Health
Co-authored papers 1
Hospital Chemnitz
Co-authored papers 1
German Cancer Research Center (DKFZ)
Co-authored papers 1